Blog

Developing molecular techniques for enhanced cereal varieties at The Field Crop Development Centre

Developing molecular techniques for enhanced cereal varieties at The Field Crop Development Centre

The Field Crop Development Centre at Olds College of Agriculture & Technology (FCDC), Alberta Canada, is a world-class research facility developing enhanced cereal varieties for feed, forage, malt, food and bio-industrial uses. The biotechnology laboratory at FCDC focuses on the application and development of molecular techniques to support variety development. Michael Holtz, Senior Research Associate, spoke to us about his group’s work with Barley and Triticale, and how PACE® genotyping has benefitted their marker development and trait development workflow.

What is your current research focus?

As a plant breeding organization, our focus is on developing varieties that meet the needs of producers and industry. Our research focuses on supporting that goal and most internal biotechnology research is focused on expanding the number of traits for which marker-assisted selection is utilized and introducing more modern selection methods, such as genomic selection, for identifying and integrating desirable traits into well-adapted germplasm.

How does SNP genotyping fit into your workflow?

We currently perform mostly marker-assisted selection (MAS) and marker-assisted gene pyramiding (MAGP). We use SNPs for QTL and marker discovery in genetic populations, for testing of markers reported by other research groups and for the routine genotyping of breeding lines to allow breeders to better select for traits of interest.

What are the challenges and benefits of working with Barley and Triticalale?

Triticale and Barley are important crops, particularly barley which is utilized as both livestock feed and a feedstock for the malting industry. That does result in challenges however as both the livestock and malting industries have differing quality targets resulting in divergent breeding goals that need to be realized. Triticale brings additional challenges as a hexaploid containing three genomes, two originating from wheat and the third from rye. In addition to the large and more complex genome, triticale receives less research funding and fewer genomic resources are available for the crop.

How do you use PACE®?

We use PACE for SNP genotyping. The primary use is to genotype breeding lines for SNPs known to be linked to or responsible for various economically relevant traits that are too time or labour-intensive to select by other methods.

What are the benefits of using PACE genotyping?

PACE benefits our work by allowing a single genotyping protocol and master mix that can be used with a variety of different markers without needing to worry about utilizing different reaction cycles or purchasing probes that are usable for only a single assay. Older legacy marker systems that necessitated gel electrophoresis have almost completely been replaced with PACE to avoid the time and labour required to run agarose gels and manually score those gels.

MORE POSTS

Investigating chicken immune responses with PACE genotyping for improved animal health and sustainability
Improving poultry immunity starts with understanding genetic diversity. Explore how researchers are using modern SNP tools to reveal what’s been hidden in the genome.
Genetic Markers To Help Improve Flavor Quality in Poultry
Discover how new HNMT gene markers can boost carnosine levels and naturally enhance poultry meat flavor.
Advancing Hemp Breeding with PACE® Genotyping: Insights from the Smart Lab at Cornell University
Researchers have developed a rapid, PACE-validated sex-marker panel for Tambaqui, enabling fast and accurate gender identification to boost efficiency and genetic gains in aquaculture breeding programs.

Our product portfolio for your PCR genotyping workflow

Our portfolio of products and services include PACE® genotyping chemistry, instruments, and lab services to streamline every step of your workflow. Designed for life sciences, biotech, and agricultural research, our high-performance reagents, reliable instruments, and expert lab support help you achieve accurate, consistent results while reducing time and costs – making science affordable.

[fibosearch]
This field is for validation purposes and should be left unchanged.
Name(Required)

Contact us

Stay up to date with all things 3CR. 

Sign up now to receive insights, updates 
and industry case studies. 

MEET OUR TEAM

Steve Asquith Managing Director
Steve began his career in the Genetics Division of GlaxoSmithKline, as part of the team establishing GSK’s high-throughput core genotyping laboratory. Steve joined KBioscience when it was first founded in 2002 and was a key driver in taking the company from a small start-up to a multi-national service laboratory, quickly growing the company’s revenue to over $7.5M p.a. Following the acquisition of Kbioscience by LGC in 2011, Steve was appointed Global Director of Operations for LGC Genomics, responsible for over 100 staff in Europe and N. America, successfully elevating the genotyping products and service business. Steve held a crucial leadership role until he left in 2016. In 2017 Steve joined forces with John Holme to create 3CR Bioscience, a new company with a mission to deliver outstanding, customer-focused genotyping products with innovation and affordability at its core.
Dr. John Holme Technical Director
John joined KBioscience shortly after it was founded, in 2003, and became Head of Technical Development, building the company’s genotyping and DNA extraction product portfolio and service delivery until 2011 when it was acquired by LGC. Post-acquisition, John was appointed Head of Technical Group for LGC Genomics, in charge of all Research & Development and Technical Support activities for the company. In this role John continued to build on the high-quality products and services provided to the companies growing customer base. During the 19 years John has worked in commercial R&D, he has co-invented numerous highly successful products including PACE®, ProbeSure, KASPâ„¢, KlearKall, KlearGene, KlearAmp and KlearTaqâ„¢, creating breakthrough offerings in genotyping and extraction and generating huge revenues for the companies he has worked in. In 2017, he joined forces with Steve Asquith and started 3CR Bioscience. John is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Dr. Nisha JainOperations Director
Nisha has been innovating since the start of her career at Geneform Technologies developing Iso-thermal Genotyping Technologies. Nisha joined KBioscience in 2008, as Senior R&D Scientist and key account Technical Support Scientist, developing KASP and Klearkall performance and coinventing two further versions of KASP. Nisha has more than 15 years’ experience working in molecular biology and genotyping technologies, with extensive experience in the areas of R&D, Quality Assurance and Customer Technical Support. She has technically assisted many giants of the industry with their protocol development and troubleshooting and continues to deliver high-quality support and guidance. In 2018, Nisha joined 3CR Bioscience as Operations Director where she continues to develop PACE and ProbeSure for an increasing range of applications, and to grow 3CR Bioscience’s new product pipeline. Nisha is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Nazma Saffin General Manager
For 20 years Nazma Saffin has worked and gained extensive expertise within the genotyping sector. Working at Kbioscience and then LGC, she has held operational leadership posts responsible for manufacturing and laboratory services. With experience of ISO 9001 implementation, production scale up and LEAN operations, Nazma has successfully led highly profitable production departments. Joining 3CR Bioscience in 2022, Nazma is committed to delivering operational excellence.
Jon Curtis Non-Executive Chair
After 8 years in The Royal Air Force, Jon moved to the Imperial Cancer Research Fund where he pioneered the use of ultra high-throughput genomic automation, capable of 46,000 PCRs per hour. In the 1990’s Jon joined GlaxoSmithKline, implementing a high-throughput genomics platform into their drug discovery pipeline. Whilst there he also developed acoustic mixing into compound management, becoming the gold standard across pharma. Jon developed the world’s first commercially viable 1536-well PCR plates, automated thermal & laser plate-sealer, plus automated liquid-handling & tip washing tools to reduce waste and costs. In 2002 Jon co-founded KBioscience with Phil Robinson, utilising ultra high-throughput PCR instrumentation & a suite of automation tools to create the company’s SNPline robotic platform, with a capacity of 250,000 PCRs/day. The business was underpinned by their ground-breaking patented genotyping chemistry, KASP™, which has over 10,000 scientific papers to date. In November 2022 Jon joined 3CR Bioscience acting as an advisor bringing his commercial and scientific experience to the company.